Predictive value of preoperative monocyte–lymphocyte ratio among patients with localized clear renal cell carcinoma of ≤7 cm on preoperative imaging

Two sporadic cases of eosinophilic solid and cystic renal cell carcinoma (ESC RCC), at our institution, are presented in this study to contribute to the growing literature on this novel renal neoplasm. The first patient was a 38-year-old female with two synchronous renal masses measuring 3.5 and 1.9 cm on preoperative imaging. The second patient was a 44-year-old female with an incidental renal mass measuring 4 cm. Both patients underwent uncomplicated radical nephrectomies. The 1.9 cm mass in the first patient was consistent with clear cell RCC. The dominant mass in the first patient and the tumor in the second patient had microscopic and macroscopic findings in keeping with ESC RCC including a tan appearance, abundant eosinophilic cytoplasm, and CK20+ and CK7− staining. Both patients had an uncomplicated course following surgery with no evidence of local recurrence or distant metastatic disease for 1 and 2 years for the first and second patient accordingly. These cases contribute to a growing body of literature regarding ESC RCC including, to our knowledge, the first reported case of synchronous ESC RCC and clear cell RCC. Further research about this novel renal neoplasm is needed.

Download Full-text

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study

Current Oncology ◽

10.3390/curroncol28020133 ◽

2021 ◽

Vol 28 (2) ◽

pp. 1402-1411

Author(s):

Koji Iinuma ◽

Koji Kameyama ◽

Kei Kawada ◽

Shota Fujimoto ◽

Kimiaki Takagi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Objective Response ◽

Predictive Biomarkers ◽

Progression Free Survival ◽

Predictive Marker ◽

Efficacy And Safety ◽

Lymphocyte Ratio

We conducted a multicenter, retrospective study to evaluate the efficacy and safety of combination nivolumab plus ipilimumab (NIVO+IPI) in 35 patients with advanced or metastatic renal cell carcinoma (mRCC). In this study, we focused on patients who received NIVO+IPI and were stratified into intermediate- or poor-risk disease according to the International Metastatic Renal Cell Carcinoma Database Consortium model at five institutions in Japan. The primary endpoint was overall survival (OS). Secondary endpoints were disease control rate (DCR), best overall response (BOR), objective response rate (ORR), and progression-free survival (PFS). In addition, we evaluated the role of inflammatory cell ratios, namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as predictive biomarkers in patients with mRCC. The median follow-up period was 1 year, and the 1-year OS rate was 95.8%. The ORR and DCR were 34.3% and 80.0%, respectively. According to BOR, four patients (11.4%) achieved complete response. According to NLR stratification, the 1-year PFS rates were 82.6% and 23.7% when the NLR was ≤4.6 and >4.6, respectively (p = 0.04). Based on PLR stratification, the 1-year PFS rates were 81.7% and 34.3% when the PLR was ≤188.1 and >188.1, respectively (p = 0.033). Although 71.4% of the patients experienced treatment-related adverse events (TRAEs) with NIVO+IPI, only four patients discontinued NIVO+IPI due to grade 3/4 TRAEs. Patients treated with NIVO+IPI as a first-line therapy for advanced or mRCC achieved relatively better oncological outcomes. Therefore, NIVO+IPI may have potential advantages and may lead to a treatment effect compared to those receiving targeted therapies. In addition, PLR >188.1 may be a useful predictive marker for mRCC patients who received NIVO+IPI.

Download Full-text

The role of neutrophil-lymphocyte ratio as a prognostic indicator in patients undergoing nephrectomy for renal cell carcinoma

Canadian Urological Association Journal ◽

10.5489/cuaj.4872 ◽

2018 ◽

Vol 12 (7) ◽

pp. E348-8 ◽

Cited By ~ 5

Author(s):

Nathan Grimes ◽

Cathal Hannan ◽

Matthew Tyson ◽

Ali Thwaini

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Renal Cell ◽

Primary Tumour ◽

Preoperative Staging ◽

Recurrence Free Survival ◽

Free Survival ◽

Neutrophil Lymphocyte Ratio ◽

Lymphocyte Ratio

Introduction: Prognosis in patients with cancer is influenced by underlying tumour biology and also the host inflammatory response to the disease. There is limited evidence to suggest that an elevated neutrophil-lymphocyte ratio (NLR) predicts a poorer prognosis in patients undergoing nephrectomy for renal cell carcinoma (RCC). The aim of this paper is to investigate if patients undergoing nephrectomy for RCC with NLR ≤4 have a better overall and recurrence-free survival than patients with NLR >4.Methods: All patients who underwent nephrectomy at a single centre between January 1, 2011 and December 31, 2014 were identified. Patients were included if postoperative histology demonstrated RCC and if preoperative NLR was available. Patients were excluded if nephrectomy was not curative intent (i.e., cytoreductive nephrectomy), if primary tumour was graded to be T3b‒4 disease, if there was presence of nodal or metastatic disease on preoperative staging, or if adequate followup notes were not available. Primary and secondary outcomes were overall survival and recurrence-free survival, respectively.Results: A total of 154 patients were included in analysis of overall survival; 146 patients were included in analysis of recurrence-free survival. Patients with NLR ≤4 had a much better overall survival than patients with NLR >4 (95% vs. 78%; p=0.0219). Patients with NLR >4 also had higher rates of recurrence (p=0.0218).Conclusions: NLR may be a useful tool in identifying patients who may benefit from more frequent surveillance in the early postoperative period and may allow clinicians to offer surveillance schemes tailored to the individual patient.

Download Full-text

Synchronous ipsilateral renal cell carcinoma and urothelial carcinoma of the renal pelvis

Canadian Urological Association Journal ◽

10.5489/cuaj.1025 ◽

2013 ◽

Vol 3 (1) ◽

pp. 64 ◽

Cited By ~ 7

Author(s):

Mike Leveridge ◽

Phillip A. Isotalo ◽

Alexander H. Boag ◽

Jun Kawakami

Keyword(s):

Renal Cell Carcinoma ◽

Urothelial Carcinoma ◽

Cell Carcinoma ◽

Renal Pelvis ◽

Renal Cell ◽

Preoperative Imaging ◽

Time Of Surgery ◽

Urological Malignancies ◽

Carcinome Urothélial ◽

Fresh Specimen

Renal cell carcinoma (RCC) and urothelial carcinoma of the upperurinary tract are not uncommon urological malignancies. Theirsimultaneous occurrence in a patient is, however, extraordinarilyrare. We report the case of a patient who underwent laparoscopicnephrectomy for suspected RCC. Preoperative imaging wassuspicious for renal pelvic involvement, which was confirmedupon bivalving the fresh specimen at the time of surgery, with thediscovery of a separate urothelium-based lesion. We discuss thisrare occurrence and our management approach.Individuellement, l’hypernéphrome et le carcinome urothélial desvoies urinaires supérieures ne sont pas des tumeurs urologiquesrares. Leur survenue simultanée chez un même patient est cependantextrêmement rare. La reconnaissance préopératoire ou intraopératoireest cruciale afin que soit effectuée la résection urétéralerequise. Nous décrivons un cas d’hypernéphrome et de carcinomeurothélial simultanés et homolatéraux.

Download Full-text

Gender- and cholesterol-specific predictive value of body mass index in renal cell carcinoma: A multicenter study

Asia-Pacific Journal of Clinical Oncology ◽

10.1111/ajco.13073 ◽

2018 ◽

Vol 15 (2) ◽

pp. e36-e42 ◽

Cited By ~ 1

Author(s):

Hyun Cheol Jeong ◽

Fahad K. Bashraheel ◽

Seok-Soo Byun ◽

Cheol Kwak ◽

Eu Chang Hwang ◽

...

Keyword(s):

Body Mass Index ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Body Mass ◽

Multicenter Study ◽

Predictive Value ◽

Renal Cell

Download Full-text

Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2013.14.3.2101 ◽

2013 ◽

Vol 14 (3) ◽

pp. 2101-2105 ◽

Cited By ~ 20

Author(s):

Ahmet Dirican ◽

Yuksel Kucukzeybek ◽

Cigdem Erten ◽

Isil Somali ◽

Lutfiye Demir ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Predictive Value ◽

Renal Cell ◽

Second Line ◽

Sunitinib Treatment ◽

Ifn Alpha

Download Full-text

Pretreatment Neutrophil-to-Lymphocyte Ratio as an Independent Predictor of Recurrence in Patients With Nonmetastatic Renal Cell Carcinoma

The Journal of Urology ◽

10.1016/j.juro.2010.05.028 ◽

2010 ◽

Vol 184 (3) ◽

pp. 873-878 ◽

Cited By ~ 136

Author(s):

Yoshio Ohno ◽

Jun Nakashima ◽

Makoto Ohori ◽

Tadashi Hatano ◽

Masaaki Tachibana

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Independent Predictor ◽

Neutrophil To Lymphocyte Ratio ◽

Lymphocyte Ratio

Download Full-text

Elevated neutrophil to lymphocyte and platelet to lymphocyte ratios predict high grade and advanced stage renal cell carcinoma

The International Journal of Biological Markers ◽

10.1177/1724600818817557 ◽

2019 ◽

Vol 34 (1) ◽

pp. 15-19 ◽

Cited By ~ 1

Author(s):

Selahattin Çalışkan

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Blood Test ◽

Neutrophil To Lymphocyte Ratio ◽

Renal Tumors ◽

High Grade ◽

Advanced Stage ◽

Platelet To Lymphocyte Ratio ◽

Lymphocyte Ratio

Introduction: Renal cell carcinoma is the most common malignancy of the kidney, which accounts 85% of all renal tumors. In recent years, the incidence of renal cell carcinoma was increased due to the widespread use of imaging techniques. The aim of this study is to investigate the clinical significance of pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios in patients with renal cell carcinomas. Methods: The patients who underwent nephrectomy for renal tumor between 2010 and 2018 in two centers were reviewed retrospectively. The age, sex, complete blood test, and pathological results were recorded. The patients who were diagnosed with other carcinomas, benign renal tumors, and missing data of age, complete blood test, and pathological results, were excluded. The patients were divided into two groups according to the T stage and Fuhrman grade, T1-2 and T3-4, G1-2 and G3-4. Results: There were 271 patients in the current study. The male to female ratio was 1.97 and the mean age of the patients was 59.37±11.62 years. Clear cell renal cell carcinoma was the most common subtype in 72.7% of the patients. Both the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio were significantly higher in patients with high-grade and advanced-stage disease than in the others. The receiver operating characteristic curve showed no significant difference between platelet to lymphocyte ratio and neutrophil to lymphocyte ratio to diagnose the high grade and stage of renal cell carcinoma. Conclusion: The neutrophil to lymphocyte and platelet to lymphocyte ratios are easily accessible biomarkers which are used for the prognosis of malignancy. The current study found that these biomarkers may predict the pathological results during the preoperative period.

Download Full-text